Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Teva Pharmaceutical Industries Limited's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).
Novantrone (mitoxantrone HCl) Injection February 2009
45th European Brain and Behaviour Society Meeting
Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.
A case of multiple evanescent white dot syndrome misdiagnosed as optic neuritis: Differential diagnosis for the neurologist.
Dimethyl Fumarate Inhibits the Nuclear Factor kappaB Pathway in Breast Cancer Cells by Covalent Modification of p65.
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.
Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.
Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis.
LKB1/STRAD promotes axon initiation during neuronal polarization.
Anti-JCV antibody levels in serum or plasma further define risk of natalizumab-associated PML.
Autoimmune Hepatitis-like reaction developing in a patient treated with Interferon beta 1a.
Immune competence after alemtuzumab treatment of multiple sclerosis.
The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
PML in a patient treated with fumaric acid.
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study.
In vivo time-lapse imaging shows dynamic oligodendrocyte progenitor behavior during zebrafish development.
Reversible pulmonary artery hypertension in association with interferon-beta therapy for multiple sclerosis.
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.
Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis.

Pages